文献速递肾移植

肾移植受者中缬更昔洛韦预防与抢先治疗的随机试验

A Randomized Trial of Valganciclovir Prophylaxis Versus Preemptive Therapy in Kidney Transplant Recipients.
PubMed 文献 · J Am Soc Nephrol · 2023-02-02

这项开放标签、单中心随机试验纳入140例肾移植受者,1:1分配至缬更昔洛韦预防组或抢先治疗组。12个月时活检证实的急性排斥发生率在预防组为13%(9/70),抢先治疗组为23%(16/70),差异无统计学意义。预防组3个月时亚临床排斥发生率较低(13% vs 29%,P=0.027),但抢先治疗组CMV DNA血症发生率更高(75% vs 44%,P<0.001)。

要点

  • 预防组12个月急性排斥发生率13%(9/70)vs 抢先治疗组23%(16/70),差异无统计学意义。
  • 预防组3个月亚临床排斥发生率13% vs 抢先治疗组29%(P=0.027)。
  • 抢先治疗组CMV DNA血症发生率75% vs 预防组44%(P<0.001)。

核心结论

  • 在肾移植受者中,与抢先治疗相比,缬更昔洛韦预防未显著降低急性排斥发生率。
  • 两种方案均能预防CMV疾病,但抢先治疗组CMV DNA血症发生率显著更高。

研究设计与样本

  • 开放标签、单中心、随机临床试验,纳入2013年6月至2018年5月招募的肾移植受者。
  • 排除CMV血清学阴性受者接受血清学阴性供者肾移植后,将140例参与者1:1随机分配至缬更昔洛韦预防组或抢先治疗组。
  • 预防组:缬更昔洛韦900 mg每日一次,CMV血清学阴性受者接受CMV血清学阳性供肾者疗程3或6个月。
  • 抢先治疗组:检测全血CMV DNA≥1000 IU/ml后启动缬更昔洛韦900 mg每日两次,连续两次检测阴性后停药;抢先治疗患者接受每周CMV PCR检测共4个月。
  • 主要结局为12个月时活检证实的急性排斥发生率。

主要发现

  • 12个月急性排斥发生率:预防组13%(9/70)vs 抢先治疗组23%(16/70),差异无统计学意义。
  • 3个月亚临床排斥发生率:预防组13% vs 抢先治疗组29%(P=0.027)。
  • 两组CMV疾病发生率均为4%。
  • CMV DNA血症发生率:抢先治疗组75% vs 预防组44%(P<0.001),差异有统计学意义。
  • 抢先治疗组较高病毒载量(≥2000 IU/ml)发作的患者比例更高,但缬更昔洛韦暴露量和中性粒细胞减少显著更低。

关键数值与推荐

  • 抢先治疗启动阈值:全血CMV DNA≥1000 IU/ml。
  • 预防组缬更昔洛韦剂量:900 mg每日一次。
  • 抢先治疗组缬更昔洛韦剂量:900 mg每日两次。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出需要进一步研究并进行长期随访,以更好地比较两种方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

SIGNIFICANCE STATEMENT: Although cytomegalovirus (CMV) infection is an important factor in the pathogenesis of kidney allograft rejection, previous studies have not determined the optimal CMV prevention strategy to avoid indirect effects of the virus. In this randomized trial involving 140 kidney transplant recipients, incidence of acute rejection at 12 months was not lower with valganciclovir prophylaxis (for at least 3 months) compared with preemptive therapy initiated after detection of CMV DNA in whole blood. However, prophylaxis was associated with a lower risk of subclinical rejection at 3 months. Although both regimens were effective in preventing CMV disease, the incidence of CMV DNAemia (including episodes with higher viral loads) was significantly higher with preemptive therapy. Further research with long-term follow-up is warranted to better compare the two approaches. BACKGROUND: The optimal regimen for preventing cytomegalovirus (CMV) infection in kidney transplant recipients, primarily in reducing indirect CMV effects, has not been defined. METHODS: This open-label, single-center, randomized clinical trial of valganciclovir prophylaxis versus preemptive therapy included kidney transplant recipients recruited between June 2013 and May 2018. After excluding CMV-seronegative recipients with transplants from seronegative donors, we randomized 140 participants 1:1 to receive valganciclovir prophylaxis (900 mg, daily for 3 or 6 months for CMV-seronegative recipients who received a kidney from a CMV-seropositive donor) or preemptive therapy (valganciclovir, 900 mg, twice daily) that was initiated after detection of CMV DNA in whole blood (≥1000 IU/ml) and stopped after two consecutive negative tests (preemptive therapy patients received weekly CMV PCR tests for 4 months). The primary outcome was the incidence of biopsy-confirmed acute rejection at 12 months. Key secondary outcomes included subclinical rejection, CMV disease and DNAemia, and neutropenia. RESULTS: The incidence of acute rejection was lower with valganciclovir prophylaxis than with preemptive therapy (13%, 9/70 versus 23%, 16/70), but the difference was not statistically significant. Subclinical rejection at 3 months was lower in the prophylaxis group (13% versus 29%, P = 0.027). Both regimens prevented CMV disease (in 4% of patients in both groups). Compared with prophylaxis, preemptive therapy resulted in significantly higher rates of CMV DNAemia (44% versus 75%, P < 0.001) and a higher proportion of patients experiencing episodes with higher viral load (≥2000 IU/ml), but significantly lower valganciclovir exposure and neutropenia. CONCLUSION: Among kidney transplant recipients, the use of valganciclovir prophylaxis did not result in a significantly lower incidence of acute rejection compared with the use of preemptive therapy. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Optimizing Valganciclovir Efficacy in Renal Transplantation (OVERT Study), ACTRN12613000554763 .

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Reischig T, Vlas T, Kacer M, et al. A Randomized Trial of Valganciclovir Prophylaxis Versus Preemptive Therapy in Kidney Transplant Recipients. J Am Soc Nephrol. 2023. PMID: 36749127. doi:10.1681/ASN.0000000000000090

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。